Dietary β-carotene and α-tocopherol combination does not inhibit atherogenesis in an ApoE-deficient mouse model

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 6, 1999, Pages 1470-1475

  Shaish, Aviv ^b   George, Jacob ^b   Gilburd, Boris ^b   Keren, Pnina ^b   Levkovitz, Hana ^b   Harats, Dror ^a  

^a SHEBA MEDICAL CENTER   (Israel)

^b NONE

Author keywords

Antibodies; Antioxidants; ApoE; Atherosclerosis; Mouse; Oxidation; tocopherol; carotene

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; APOLIPOPROTEIN E; BETA CAROTENE; LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROGENESIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HYPERLIPOPROTEINEMIA TYPE 3; LIPOPROTEIN BLOOD LEVEL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; VITAMIN INTAKE;

EID: 0033022436     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.6.1470     Document Type: Article

References (43)

1. Ross R. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature. 1993;362:801-809.
2. Goldstein JL, Ho YK, Basu SK. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci U S A. 1979;76:333-337.
3. Henriksen T, Mahoney EM, Steinberg D. Enhanced macrophage degradation of low density lipoprotein previously incubated with cultured endothelial cells: Recognition by receptors for acetylated low density lipoproteins. Proc Natl Acad Sci U S A. 1981;78:6499-6503.
4. Haberland ME, Fong D, Cheng L. Malondialdehyde-altered protein occurs in atheroma of Watanabe heritable hyperlipidemic rabbits. Science. 1988;241:215-218.
5. Steinbrecher UP, Parthasarathy S, Loake DS, Witztum JL, Stemberg D. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci U S A. 1984;81:3883-3887.
6. Heinecke JW, Rosen H, Chait A. Iron and copper promote modification of low density lipoprotein by human arterial smooth muscle cells in culture. J Clin Invest. 1984;74:1890-1894.
7. Gaziano JM., Hennekens CH. The role of beta carotene in the prevention of cardiovascular disease. Ann N Y Acad Sci. 1993;691:148-155.
8. Hennekens CH, Buring JE, Manson JE. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med. 1996;334:1145-1149.
9. Burton GW, Ingold KU. Beta-carotene: An unusual type of lipid anti-oxidant. Science. 1984;224:569-573.
10. Jialal IEP, Norkus LC, Grundy SM. Beta-carotene inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta. 1991; 1086:134-138.
11. Princen HM, Poppel GGV, Vogelezang C, Buytenhek R, Kok FJ. Supplementation with vitamin E but not beta-carotene in vivo protects low density lipoprotein from lipid peroxidation in vitro: Effect of cigarette smoking. Arterioscler Thromb. 1992;12:554-562.
12. Reaven PD, Khouw A, Beltz WF, Parthasarathy S, Witztum JL. Effect of dietary antioxidant combinations in humans: Protection of LDL by vitamin E but not by beta-carotene. Arterioscler Thromb. 1993;13: 590-600.
13. Lavy A, Ben-Amotz A, Aviram M. Preferential inhibition of LDL oxidation by the all-trans isomer of beta-carotene in comparison with 9-cis beta-carotene. Eur J Clin Biochem. 1993;31:83-90.
14. Shaish A, Daugherty A, O'Sullivan F, Schonfeld G, Heinecke J. Beta-carotene inhibits atherosclerosis in hypercholesterolemic rabbits. J Clin Invest. 1995;96:2075-2082.
15. Sun J, Giraud DW, Moxley RA, Driskel JA. Beta-carotene and alpha-to-copherol inhibit the development of atherosclerotic lesions in hypercholesterolemic rabbits. Int J Vitam Res. 1997;67:155-163.
16. Gaziano JM, Hatta A, Flynn M, Johnson EJ, Krinsky NI, Ridker PM, Hennekens CH, Frei B. Supplementation with β-carotene in vivo and in vitro does not inhibit low density lipoprotein oxidation. Atherosclerosis. 1995;112:187-195.
17. Lynch SM, Frei B. Animal studies. In: Frei B, ed. Natural Antioxidants in Human Health and Disease. Orlando, FL: Academic Press; 1994: 353-386.
18. Daugherty A, Roselaar SE. Lipoprotein oxidation as a mediator of atherogenesis: Insights from pharmacological studies. Cardiovasc Res. 1995; 29:297-311.
19. Tangirala RK, Casanada F, Miller E, Witztum JL, Steinberg D, Palinski W. Effect of the antioxidant N, N′-Diphenyl 1,4-Phenylenediamine (DPPD) on atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vase Biol. 1994;15:1625-1630.
20. Fuhrman B, Buch S, Vaya J, Belinsky PA, Coleman R, Hayek T, Aviram M. Licorice extract and its major polyphenol glabridin protect low-density lipoprotein against lipid peroxidation: In vitro and ex vivo studies in humans and in atherosclerotic apolipoprotein E-deficient mice. Am J Clin Nutr. 1997;66:267-275.
21. Zhang SH, Reddick RL, Avdievich E, Surles LK, Jones RG, Reynolds JB, Quarfordt S. H., Maeda N. Paradoxical enhancement of atherosclerosis by probucol treatment in apolipoprotein E-deficient mice. J Clin Invest. 1997;99:2858-2866.
22. Palozza P, NI. Krinsky. Antioxidant effects of carotenoids in vivo and in vitro: An overview. Methods Enzymol. 1992;213:403-429.
23. Furr HC. Reversed-phase high performance liquid chromatography of retinyl esters. Methods Enzymol 1990;189:85-94.
24. Palinski W, Ord VA, Plump AS, Breslow JL, Steinberg D, Witztum JL. ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis: Demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum. Arterioscler Thromb. 1994;14:605-616.
25. Esterbauer H, Striegl G, Puhl H, Rotheneder M. Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radic Res Commun. 1989;6:67-75.
26. Keaney JF Jr, Gaziano JM, Xu A, Frei B, Curran-Celentano J, Shwaery GT, Loscalzo J, Vita JA. Dietary antioxidants preserve endothelium-dependent vessel relaxation in cholesterol-fed rabbits. Proc Natl Acad Sci U S A. 1993;90:11880-11884.
27. Folman Y, Russell RM, Tang GW, Wolf G. Rabbits fed beta-carotene have higher serum levels of all-trans retinoic acid than those receiving no beta-carotene. Br J Nutr. 1989;62:195-201.
28. Willett WC, Stampfer MJ, Underwood BA, Taylor JO, Hennekens CH. Vitamins A, E, and carotene: Effects of supplementation on their plasma levels. Am J Clin Nutr. 1983;38:559-566.
29. Bjomson LK, Kayden HJ, Miller E, Moshell AN. The transport of α-tocopherol and β-carotene in human blood. J Lipid Res. 1976;17: 343-352.
30. Palinski W, Rosenfeld ME, Yla-Hertulla S, Gurtner GC, Socher SS, Butler SW, Parthasarathy S, Carew TE, Steinberg D, Witztum JL. Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci U S A. 1989;86:1372-1376.
31. Palinski W, Miller E, Witztum JL. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc Natl Acad Sci U S A. 1995;92:821-825.
32. Ameli S, Hultgardh-Nilsson A, Regnstrom J, Calara F, Yano J, Cercek B, Shah PK, Nilsson J. Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol. 1996;16:1074-1079.
33. George J, Afek A, Gilburd B, Levkovitz H, Shaish A, Goldberg I, Kopolovic Y, Wick G, Shoenfeld Y, Harats D. Hyperimmunization of apo-E-deficient mice with homologous malondialdehyde low-density lipoprotein suppresses early atherogenesis. Atherosclerosis. 1998;138: 147-152.
34. Neuzil J, Christison JK, Inheanacho E, Fragonas JC, Zammit V, Hunt, Stocker R. Radical-induced lipoprotein and plasma lipid oxidation in normal and apolipoprotein E gene knockout (apoE-/-) mice: ApoE-/-mouse as a model for testing the role of tocopherol-mediated peroxidation in atherogenesis. J Lipid Res. 1988;39:354-368.
35. Fruebis J, Steinberg D, Dresel HA, Carew TE. A comparison of the anti-atherogenic effects of probucol and of a structural analogue in low density lipoprotein receptor-deficient rabbits. J Clin Invest. 1994;94:392-398.
36. Sasahara M, Raines EW, Chait A, Carew TE, Steinberg D, Wahl PW, Ross R. Inhibition of hypercholesterolemia-induced atherosclerosis in nonhuman primate by Probucol: I. Is the extent of atherosclerosis related to resistance of LDL to oxidation? J Clin Invest. 1994;94:155-164.
37. Parthasarathy S, Young SG, Witztum JL, Pittman RC, Steinberg D. Probucol inhibits oxidative modification of low density lipoprotein. J Clin Invest. 1986;77:641-644.
38. Fruebis J, Steinberg D, Dresel HA, Carew TE. A comparison of the antiatherogenic effects of probucol and of a structural analogue of probucol in low density lipoprotein receptor-deficient rabbits. J Clin Invest. 1994;94:392-398.
39. Munday JS, Thompson KG, James KAC, Manktelow BW. Dietary anti-oxidants do not reduce fatty streak formation in the C57BL/6 mouse atherosclerosis model. Anerioscler Thromh Vasc Biol. 1997;18:114-119.
40. Westrope KL, Miller RA, Wilson RB. Vitamin E in a rabbit model of endogenous hypercholesterolemia and atherosclerosis. Nutr Rep Int. 1982;25:83-88.
41. Wilson RB, Middleton CC, Sun GY. Vitamin E, antioxidants and lipid peroxidation in experimental atherosclerosis of rabbits. J Nutr 1978;108: 1858-1867.
42. Mahley RW. Development of accelerated atherosclerosis: concepts derived from cell biology and animal models. Arch Pathol Lab Med. 1983;107:393-399.
43. Pratico D, Tangirala RK, Rader DJ, Rokach J, FitzGerald A. Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in apoE-deficient mice. Nat Med 1998;4:1189-1192.